Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

Blood (2024) 144 (Supplement 1): 513.

https://doi.org/10.1182/blood-2024-204888

Published: 2024

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease

Blood (2023) 142 (Supplement 1): 5000.

https://doi.org/10.1182/blood-2023-188963

Published: 2023

Journal Articles

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Miriam Y Kim, Matthew L. Cooper, Julie K. Ritchey, Julie O'Neal, John DiPersio

Blood (2023) 142 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2023-186015

Published: 2023

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy

Michael Slade, Michael P. Rettig, Zachary David Crees, Neha Mehta-Shah, Todd A Fehniger, Amanda F Cashen, Iskra Pusic, Geoffrey L Uy, Peter Westervelt, John DiPersio, Armin Ghobadi

Blood (2023) 142 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2023-172439

Published: 2023

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2023-189762

Published: 2023

Journal Articles

Identifying Surface Protein Markers for AML Immunotherapy

Omar M. Ibrahim, Michael P. Rettig, Ezhilarasi Chendamarai, Reyka G. Jayasinghe, Li Ding, John DiPersio

Blood (2023) 142 (Supplement 1): 6809.

https://doi.org/10.1182/blood-2023-187831

Published: 2023

Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne

Blood (2023) 142 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2023-180990

Published: 2023

Journal Articles

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

Parmeshwar N Amatya, Jingyu Xiang, Julie O'Neal, Julie K. Ritchey, Alun J Carter, Matthew L. Cooper, John DiPersio

Blood (2023) 142 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2023-187449

Published: 2023

Journal Articles

Long Non-Coding RNA LINC00XPRR Is Upregulated in Newly Diagnosed Multiple Myeloma Promoting Poor Response to High-Dose Melphalan with Autologous Stem Cell Transplantation and Three-Drug Regimen

Richa Mishra, Katelyn Bagwill, Savannah Gonzales, Vanessa Brizuela, Prasanth Thunuguntla, Yoon Jae Chang, Reyka G. Jayasinghe, Julie Fortier, Mark A. Schroeder, Li Ding, Ravi Vij, John DiPersio, Jessica Silva-Fisher

Blood (2023) 142 (Supplement 1): 4668.

https://doi.org/10.1182/blood-2023-180011

Published: 2023

Journal Articles

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, Pedro Dorlhiac-Llacer, Ricardo Pasquini, John DiPersio, Martin C. Müller, Jerald P. Radich, H. Jean Khoury, Nina Khoroshko, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman

Blood (2009) 113 (25): 6322–6329.

https://doi.org/10.1182/blood-2008-11-186817

Published: 2009

Journal Articles

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

Richard Walgren, MD, PhD, Crystal Dao, MA, Frederieke Kreisel, MD, Peter Westervelt, MD, PhD, Camille Abboud, MD, Timothy Graubert, MD, Amanda Cashen, MD, Geoffrey Uy, MD, Feng Gao, MD, John DiPersio, MD, PhD, Ravi Vij, MD

Blood (2007) 110 (11): 1451.

https://doi.org/10.1182/blood.V110.11.1451.1451

Published: 2007

Journal Articles

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

John DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Ivana Micallef, MD, J. Angell, MS, G. Bridger, PhD, Gary Calandra, MD, for the 3102 Investigators7

Blood (2007) 110 (11): 445.

https://doi.org/10.1182/blood.V110.11.445.445

Published: 2007

Journal Articles

Generation of T reg -Like Cells from CD4+CD25- T Cells Via Epigenetic Modification Using a Demethylating Agent Decitabine.

Jaebok Choi, PhD, Julie Ritchey, John DiPersio, MD, PhD

Blood (2007) 110 (11): 62.

https://doi.org/10.1182/blood.V110.11.62.62

Published: 2007

Journal Articles

Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100

Rebecca M. Shepherd, Benjamin J. Capoccia, Steven M. Devine, John DiPersio, Kathryn M. Trinkaus, David Ingram, Daniel C. Link

Blood (2006) 108 (12): 3662–3667.

https://doi.org/10.1182/blood-2006-06-030577

Published: 2006

Journal Articles

A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease

Margaret L. MacMillan, Daniel Couriel, Daniel J. Weisdorf, Gisela Schwab, Nancy Havrilla, Thomas R. Fleming, Saling Huang, Lorin Roskos, Shimon Slavin, Richard K. Shadduck, John DiPersio, Mary Territo, Steve Pavletic, Charles Linker, Helen E. Heslop, H. Joachim Deeg, Bruce R. Blazar

Blood (2006) 109 (6): 2657–2662.

https://doi.org/10.1182/blood-2006-08-013995

Published: 2006

Journal Articles

AMD3100 + G-CSF Improves Hematopoietic Progenitor Cell (HPC) Collection in Patients with Hodgkin’s Disease (HD).

Amanda Cashen, MD, Steven Devine, MD, Ravi Vij, MD, John DiPersio, MD

Blood (2005) 106 (11): 1979.

https://doi.org/10.1182/blood.V106.11.1979.1979

Published: 2005

Journal Articles

A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Amanda Cashen, MD, Ajit Shah, PhD, Angela Helget, Laura Todt, Nicholas Fisher, John DiPersio, MD, PhD

Blood (2005) 106 (11): 1854.

https://doi.org/10.1182/blood.V106.11.1854.1854

Published: 2005

Journal Articles

Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT.

Michael Rettig, PhD, Julie Ritchey, Julie Prior, David Piwnica-Worms, MD/PhD, Mark Bonyhadi, PhD, John DiPersio, MD/PhD.

Blood (2005) 106 (11): 5257.

https://doi.org/10.1182/blood.V106.11.5257.5257

Published: 2005

NARROW

Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Identifying Surface Protein Markers for AML Immunotherapy

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

Long Non-Coding RNA LINC00XPRR Is Upregulated in Newly Diagnosed Multiple Myeloma Promoting Poor Response to High-Dose Melphalan with Autologous Stem Cell Transplantation and Three-Drug Regimen

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

Generation of T reg -Like Cells from CD4+CD25- T Cells Via Epigenetic Modification Using a Demethylating Agent Decitabine.

Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100

A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease

AMD3100 + G-CSF Improves Hematopoietic Progenitor Cell (HPC) Collection in Patients with Hodgkin’s Disease (HD).

A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only